<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40371797</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1723-8617</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>World psychiatry : official journal of the World Psychiatric Association (WPA)</Title><ISOAbbreviation>World Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Risk of relapse during tapering of antipsychotic medication after a first psychotic episode: association with D2 receptor affinity but not with tapering speed.</ArticleTitle><Pagination><StartPage>240</StartPage><EndPage>249</EndPage><MedlinePgn>240-249</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/wps.21315</ELocationID><Abstract><AbstractText>While antipsychotic maintenance treatment effectively prevents relapse after a first psychotic episode, many remitted antipsychotic users wish to reduce or discontinue their medication, due to side effects, long-term health concerns, stigma, or the desire to regain autonomy. Current guidelines suggest gradual tapering, but what the optimal speed of this tapering should be, especially in patients who remitted from a first psychotic episode, remains unclear. Furthermore, D2 receptor affinity of the antipsychotic drug may also affect relapse risk. This study examined relapse risk and time to relapse, within the first 18 months after remission from a first psychotic episode, in 227 individuals who tapered antipsychotic medication. Relapse was defined dichotomously using consensus criteria based on the Positive and Negative Syndrome Scale, hospitalization for psychosis, or explicit clinical judgement of the treating psychiatrist. Tapering speed (in olanzapine equivalents mg/day) was calculated as the difference of antipsychotic dose between the start and the end of tapering, divided by the number of days in between. Antipsychotics were classified into partial D2 agonists, or antagonists with low or high D2 affinity. Logistic and Cox proportional hazards regression analyses were controlled for age, sex, cannabis use, and duration of first psychotic episode, as well as for differences in clinical and sociodemographic characteristics between the three drug D2 affinity groups using inverse probability of treatment weighting. During the follow-up period, 45.8% (N=104) of participants experienced a relapse after tapering. The average tapering speed was 10 mg olanzapine equivalents over 75 days, with an average tapering duration of 124 days (range: 6-334 days). Logistic regression analysis showed that the tapering speed did not predict the risk of relapse (z=0.989, p=0.323). Compared with users of high D2&#xa0;affinity antagonists (N=57), patients using low D2&#xa0;affinity antagonists (N=116) and partial D2 agonists (N=54) had a lower risk of relapse (respectively, z=-2.104; odds ratio, OR=0.48, p=0.035; and z=-2.278, OR=0.44, p=0.023). Users of high D2 affinity antagonists had a shorter time between the end of tapering and relapse (mean: 280 days) than low D2 affinity antagonist users (mean: 351 days, p=0.027) and partial D2 agonist users (mean: 357 days, p=0.040). Thus, D2 receptor affinity of the antipsychotic was more important than tapering speed in predicting psychotic relapse risk in individuals remitted from a first psychotic episode. Users of high D2 affinity antipsychotics had an about twice higher risk of relapse than users of other types of antipsychotics. This higher risk of relapse after tapering should be regarded as a relevant factor when selecting an antipsychotic drug for people with a first psychotic episode. For patients using strong D2 antagonists after remission from a first psychotic episode, extra monitoring during tapering is required.</AbstractText><CopyrightInformation>&#xa9; 2025 World Psychiatric Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gangadin</LastName><ForeName>Shiral S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Center for Clinical Neuroscience and Cognition, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University Medical Centre&#xa0;Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Beer</LastName><ForeName>Franciska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Clinical Neuroscience and Cognition, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijnen</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre of Economic Evaluations and Machine Learning, Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Begemann</LastName><ForeName>Marieke</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Clinical Neuroscience and Cognition, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University Medical Centre&#xa0;Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Beveren</LastName><ForeName>Nico</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Parnassia Group for Mental Health Care, The Hague, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Erasmus Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boonstra</LastName><ForeName>Nynke</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Healthcare, NHL Stenden University of Applied Sciences, Leeuwarden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KieN VIP Mental Health Care Services, Leeuwarden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, UMC Utrecht Brain Center, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Haan</LastName><ForeName>Lieuwe</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Amsterdam University Medical Centre - location AMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, Arkin Mental Health Care, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kikkert</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Research, Arkin Mental Health Care, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koops</LastName><ForeName>Sanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Clinical Neuroscience and Cognition, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University Medical Centre&#xa0;Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Os</LastName><ForeName>Jim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, UMC Utrecht Brain Center, Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, Mental Health and Neuroscience Research Institute, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's Health Partners Department of Psychosis Studies, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veling</LastName><ForeName>Wim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Medical Centre&#xa0;Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiersma</LastName><ForeName>Sybren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Early Intervention Psychosis Team, GGZ inGeest Specialized Mental Health Care, Hoofddorp, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>HAMLETT&#x2010;OPHELIA Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Sommer</LastName><ForeName>Iris E C</ForeName><Initials>IEC</Initials><AffiliationInfo><Affiliation>Center for Clinical Neuroscience and Cognition, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University Medical Centre&#xa0;Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>World Psychiatry</MedlineTA><NlmUniqueID>101189643</NlmUniqueID><ISSNLinking>1723-8617</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antipsychotic medication</Keyword><Keyword MajorTopicYN="N">D2 receptor affinity</Keyword><Keyword MajorTopicYN="N">dopamine supersensitivity</Keyword><Keyword MajorTopicYN="N">dose reduction</Keyword><Keyword MajorTopicYN="N">first episode psychosis</Keyword><Keyword MajorTopicYN="N">partial D2 agonists</Keyword><Keyword MajorTopicYN="N">relapse</Keyword><Keyword MajorTopicYN="N">tapering</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>15</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>15</Day><Hour>12</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>15</Day><Hour>7</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40371797</ArticleId><ArticleId IdType="doi">10.1002/wps.21315</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Alvarez&#x2010;Jimenez M, Priede A, Hetrick SE et&#xa0;al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta&#x2010;analysis of longitudinal studies. Schizophr Res 2012;139:116&#x2010;28.</Citation></Reference><Reference><Citation>Taipale H, Tanskanen A, Correll CU et&#xa0;al. Real&#x2010;world effectiveness of antipsychotic doses for relapse prevention in patients with first&#x2010;episode schizophrenia in Finland: a nationwide, register&#x2010;based cohort study. Lancet Psychiatry 2022;9:271&#x2010;9.</Citation></Reference><Reference><Citation>Huhn M, Nikolakopoulou A, Schneider&#x2010;Thoma J et&#xa0;al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi&#x2010;episode schizophrenia: a systematic review and network meta&#x2010;analysis. Lancet 2019;394:939&#x2010;51.</Citation></Reference><Reference><Citation>Correll CU, Martin A, Patel C et&#xa0;al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia 2022;8:5.</Citation></Reference><Reference><Citation>Crellin NE, Priebe S, Morant N et&#xa0;al. An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders. BMC Psychiatry 2022;22:185.</Citation></Reference><Reference><Citation>Keogh B, Murphy E, Doyle L et&#xa0;al. Mental health service users experiences of medication discontinuation: a systematic review of qualitative studies. J Ment Health 2022;31:227&#x2010;38.</Citation></Reference><Reference><Citation>St&#xfc;rup AE, Nordentoft M, Jimenez&#x2010;Solem E et&#xa0;al. Discontinuation of antipsychotics in individuals with first&#x2010;episode schizophrenia and its association to functional outcomes, hospitalization and death: a register&#x2010;based nationwide follow&#x2010;up study. Psychol Med 2023;53:5033&#x2010;41.</Citation></Reference><Reference><Citation>Cheng Z, Yuan Y, Han X et&#xa0;al. Rates and predictors of one&#x2010;year antipsychotic treatment discontinuation in first&#x2010;episode schizophrenia: results from an open&#x2010;label, randomized, &#x201c;real world&#x201d; clinical trial. Psychiatry Res 2019;273:631&#x2010;40.</Citation></Reference><Reference><Citation>Bowtell M, Eaton S, Thien K et&#xa0;al. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schizophr Res 2018;195:231&#x2010;6.</Citation></Reference><Reference><Citation>Wunderink L, Nieboer RM, Wiersma D et&#xa0;al. Recovery in remitted first&#x2010;episode psychosis at 7 years of follow&#x2010;up of an early dose reduction/discontinuation or maintenance treatment strategy. JAMA Psychiatry 2013;70:913&#x2010;20.</Citation></Reference><Reference><Citation>M&#xf8;lgaard SN, Nielsen M&#xd8;, Roed K et&#xa0;al. Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia &#x2013; a case series. BMC Psychiatry 2024;24:240.</Citation></Reference><Reference><Citation>Bogers JPAM, Hambarian G, Walburgh Schmidt N et&#xa0;al. Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia. A meta&#x2010;analysis of randomized controlled trials. Schizophr Bull 2023;49:11&#x2010;23.</Citation></Reference><Reference><Citation>Koops S, Allott K, de Haan L et&#xa0;al. Addressing the evidence to practice gap: what to expect from international antipsychotic dose reduction studies in the tapering anti&#x2010;psychotics and evaluating recovery consortium. Schizophr Bull 2024;50:5&#x2010;8.</Citation></Reference><Reference><Citation>Bogers JPAM, Hambarian G, Michiels M et&#xa0;al. Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia: a systematic review and meta&#x2010;analysis. Schizophr Bull Open 2023;49:11&#x2010;23.</Citation></Reference><Reference><Citation>Schlier B, Buck L, M&#xfc;ller R et&#xa0;al. Time&#x2010;dependent effect of antipsychotic discontinuation and dose reduction on social functioning and subjective quality of life &#x2013; a multilevel meta&#x2010;analysis. EClinicalMedicine 2023;65:102291.</Citation></Reference><Reference><Citation>Horowitz MA, Jauhar S, Natesan S et&#xa0;al. A method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophr Bull 2021;47:1116&#x2010;29.</Citation></Reference><Reference><Citation>Liu CC, Hsieh MH, Chien YL et&#xa0;al. Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2&#x2010;year randomized controlled trial with a naturalistic cohort. Psychol Med 2023;53:7078&#x2010;86.</Citation></Reference><Reference><Citation>Horowitz MA, Murray RM, Taylor D. Tapering antipsychotic treatment. JAMA Psychiatry 2021;78:125&#x2010;6.</Citation></Reference><Reference><Citation>Tadokoro S, Okamura N, Sekine Y et&#xa0;al. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull 2012;38:1012&#x2010;20.</Citation></Reference><Reference><Citation>Chouinard G, Samaha AN, Chouinard VA et&#xa0;al. Antipsychotic&#x2010;induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom 2017;86:189&#x2010;219.</Citation></Reference><Reference><Citation>Wilson M, Harris M, Pereira M et&#xa0;al. Predictors of hospitalisation and recovery following full antipsychotic discontinuation in first episode psychosis. A naturalistic retrospective cohort study. Schizophr Res 2023;261:269&#x2010;74.</Citation></Reference><Reference><Citation>Begemann MJH, Thompson IA, Veling W et&#xa0;al. To continue or not to continue? Antipsychotic medication maintenance versus dose&#x2010;reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single&#x2010;blind randomized controlled trial. Trials 2020;21:147.</Citation></Reference><Reference><Citation>Andreasen NC. The Comprehensive Assessment of Symptoms and History (CASH). Arch Gen Psychiatry 1992;49:615&#x2010;23.</Citation></Reference><Reference><Citation>Jones SH, Thornicroft G, Coffey M et&#xa0;al. A brief mental health outcome scale &#x2013; reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995;166:654&#x2010;9.</Citation></Reference><Reference><Citation>Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261&#x2010;76.</Citation></Reference><Reference><Citation>Bouwmans C, De Jong K, Timman R et&#xa0;al. Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC&#x2010;P). BMC Health Serv Res 2013;13:217.</Citation></Reference><Reference><Citation>Leucht S, Crippa A, Siafis S et&#xa0;al. Dose&#x2010;response meta&#x2010;analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry 2020;177:342&#x2010;53.</Citation></Reference><Reference><Citation>Leucht S, Samara M, Heres S et&#xa0;al. Dose equivalents for second&#x2010;generation antipsychotics: the minimum effective dose method. Schizophr Bull 2014;40:314&#x2010;26.</Citation></Reference><Reference><Citation>Leucht S, Samara M, Heres S et&#xa0;al. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull 2016;42(Suppl. 1):S90&#x2010;4.</Citation></Reference><Reference><Citation>Siafis S, Brandt L, McCutcheon RA et&#xa0;al. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence&#x2010;based criteria derived by equipercentile linking and diagnostic test accuracy meta&#x2010;analysis. Lancet Psychiatry 2024;11:36&#x2010;46.</Citation></Reference><Reference><Citation>Kaar SJ, Natesan S, McCutcheon R et&#xa0;al. Antipsychotics: mechanisms underlying clinical response and side&#x2010;effects and novel treatment approaches based on pathophysiology. Neuropharmacology 2020;172:107704.</Citation></Reference><Reference><Citation>Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34:3661&#x2010;79.</Citation></Reference><Reference><Citation>Bowtell M, Ratheesh A, McGorry P et&#xa0;al. Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review. Schizophr Res 2018;197:9&#x2010;18.</Citation></Reference><Reference><Citation>Dixon WJ. Simplified estimation from censored normal samples. Ann Math Stat 1960;31:385&#x2010;91.</Citation></Reference><Reference><Citation>R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2018.</Citation></Reference><Reference><Citation>Servonnet A, Samaha AN. Antipsychotic&#x2010;evoked dopamine supersensitivity. Neuropharmacology 2020;163:107630.</Citation></Reference><Reference><Citation>Yin J, Barr AM, Ramos&#x2010;Miguel A et&#xa0;al. Antipsychotic induced dopamine supersensitivity psychosis: a comprehensive review. Curr Neuropharmacol 2017;15:174&#x2010;83.</Citation></Reference><Reference><Citation>Amada N, Akazawa H, Ohgi Y et&#xa0;al. Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5&#x2010;HT2A receptors in rats. Neuropsychopharmacol Rep 2019;39:279&#x2010;88.</Citation></Reference><Reference><Citation>El Hage C, B&#xe9;dard AM, Samaha AN. Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function. Neuropharmacology 2015;99:715&#x2010;25.</Citation></Reference><Reference><Citation>Ginovart N, Wilson AA, Hussey D et&#xa0;al. D2&#x2010;receptor upregulation is dependent upon temporal course of D2&#x2010;occupancy: a longitudinal [11C]&#x2010;raclopride PET study in cats. Neuropsychopharmacology 2009;34:662&#x2010;71.</Citation></Reference><Reference><Citation>Kusumi I, Takahashi Y, Suzuki K et&#xa0;al. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5&#x2010;HT2A receptors in the rat brain. J Neural Transm 2000;107:295&#x2010;302.</Citation></Reference><Reference><Citation>Andrade C. Psychotropic drugs with long half&#x2010;lives. J Clin Psychiatry 2022;83:22f14593.</Citation></Reference><Reference><Citation>Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr 2015;38:152&#x2010;5.</Citation></Reference><Reference><Citation>Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry 1997;58(Suppl. 7):37&#x2010;40.</Citation></Reference><Reference><Citation>Taylor D, Chithiramohan R, Grewal J et&#xa0;al. Dopamine partial agonists: a discrete class of antipsychotics. Int J Psychiatry Clin Pract 2023;27:272&#x2010;84.</Citation></Reference><Reference><Citation>McCutcheon RA, Taylor D, Rubio J et&#xa0;al. Does slow and steady win the race? Rates of antipsychotic discontinuation, antipsychotic dose, and risk of psychotic relapse. Schizophr Bull 2024;50:513&#x2010;20.</Citation></Reference><Reference><Citation>Horowitz MA, Moncrieff J, de Haan L et&#xa0;al. Tapering antipsychotic medication: practical considerations. Psychol Med 2022;52:32&#x2010;5.</Citation></Reference><Reference><Citation>Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007;89:129&#x2010;39.</Citation></Reference><Reference><Citation>Kishi T, Ikuta T, Matsui Y et&#xa0;al. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first&#x2010;episode psychosis: a meta&#x2010;analysis. Psychol Med 2019;49:772&#x2010;9.</Citation></Reference><Reference><Citation>Correll CU, Galling B, Pawar A et&#xa0;al. Comparison of early intervention services vs treatment as usual for early&#x2010;phase psychosis: a systematic review, meta&#x2010;analysis, and meta&#x2010;regression. JAMA Psychiatry 2018;75:555&#x2010;65.</Citation></Reference><Reference><Citation>Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug&#x2010;induced movement disorder and resulting iatrogenic psychiatric&#x2010;like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 2008;77:69&#x2010;77.</Citation></Reference><Reference><Citation>Storck W, de Laportali&#xe8;re TT, Yrondi A et&#xa0;al. Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022. Psychopharmacology 2024;241:1205&#x2010;12.</Citation></Reference><Reference><Citation>Horowitz MA, Murray RM, Taylor D. Withdrawal&#x2010;associated relapse is a potential source of bias. Lancet Psychiatry 2021;8:747&#x2010;8.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>